Metabolic Activation of Atomoxetine Mediated by Cytochrome P450 2D6.

Atomoxetine (ATX) is a neurological drug widely used for the treatment of attention deficit-hyperactivity disorder. Liver injury has been documented in patients administered ATX. The mechanism of ATX's toxic action is less clear. This study is aimed to characterize reactive metabolites of ATX in vitro and in vivo to assist our understanding of the mechanisms of ATX hepatotoxicity. A hydroxylated metabolite, along with an O-dealkylation metabolite, was found in ATX-supplemented rat liver microsome incubations. Additionally, two glutathione (GSH) conjugates and two N-acetylcysteine (NAC) conjugates were observed in rat liver microsome incubations containing ATX, NADPH, and GSH or NAC. The corresponding GSH conjugates and NAC conjugates were found in bile and urine of ATX-treated rats, respectively. Recombinant P450 enzyme incubation study demonstrated that CYP2D6 dominated the metabolic activation of ATX. The insights gained from this study may be of assistance to illuminate the mechanisms of ATX-induced hepatotoxicity.

Ultrasonic assisted magnetic dispersive solid phase microextraction for pre concentration of serotonin-norepinephrine reuptake inhibitor drugs.

A simple and sensitive ultrasonic assisted magnetic dispersive solid phase microextraction method (UAMDSPME) coupled with high performance liquid chromatography was developed to determine serotonin-norepinephrine reuptake inhibitor drugs including duloxetine (DUL), venlafaxine (VEN) and atomoxetine (ATO) in human urine, river water and well water samples. A novel and efficient SPME sorbent, magnetic p-Phenylenediamine functionalized reduced graphene oxide Quantum Dots@ Ni nanocomposites (MrGOQDs-PD@ Ni), was prepared and applied for extraction of the analytes. Several effective parameters on the extraction efficiency of the analytes were investigated and optimized with experimental design approach. The performance of MrGOQDs-PD@ Ni as the SPME sorbent for the extraction of DUL, VEN and ATO was then compared with magnetic graphene oxide (MGO@Fe3O4) and magnetic reduced graphene oxide (MrGO@ Ni). Under the optimized conditions for the MrGOQDs-PD@ Ni sorbent, the intra-day relative standard deviations (RSDs, n = 5) and the limits of detections (LODs) were lower than 4.6% and 1.1 ngmL-1, respectively. Moreover, the good linear ranges were observed in wide concentration ranges with R-squared larger than 0.9878. Finally, the enrichment factors in the range of 137-183 and the recovery percentage in the range of 89.2-94.8% were obtained to determine the analytes in the real samples.

Quantification of Methylphenidate, Dexamphetamine, and Atomoxetine in Human Serum and Oral Fluid by HPLC With Fluorescence Detection.

BACKGROUND: For psychostimulants, a marked individual variability in the dose-response relationship and large differences in plasma concentrations after similar doses are known. Therefore, optimizing the efficacy of these drugs is at present the most promising way to exploit their full pharmacological potential. Moreover, it seems important to examine oral fluid as less invasive biological matrix for its benefit in therapeutic drug monitoring for patients with hyperkinetic disorder. METHODS: A high-performance liquid chromatography method for quantification of methylphenidate (MPH), dexamphetamine (DXA), and atomoxetine in serum and oral fluid has been developed and validated. The analytical procedure involves liquid-liquid extraction, derivatization with 4-(4,5-diphenyl-1H-imidazol-2-yl)benzoyl chloride as a label and chromatographic separation on a Phenomenex Gemini-NX C18 analytical column using gradient elution with water-acetonitrile. The derivatized analytes were detected at 330 nm (excitation wavelength) and 440 nm (emission wavelength). To examine the oral fluid/serum ratios, oral fluid samples were collected simultaneously to blood samples from patients with hyperkinetic disorder. RESULTS: The method allows quantification of all analytes in serum and oral fluid within 16 minutes under the same or similar conditions. Oral fluid/serum ratios for MPH and DXA were highly variable and showed an accumulation of these drugs in oral fluid. CONCLUSIONS: The developed method covers the determination of MPH, DXA, and atomoxetine concentrations in serum and oral fluid after the intake of therapeutic doses. Oral fluid samples are useful for the qualitative detection of MPH and DXA.

Capillary electrophoresis coupled with electrochemiluminescence for determination of atomoxetine hydrochloride and the study on its interactions with three proteins.

A simple, rapid and sensitive method for the determination of atomoxetine hydrochloride (AH) by capillary electrophoresis with electrochemiluminescence detection (CE-ECL) using tris(2,2'-bipyridyl) ruthenium (II) was developed. Under optimized conditions, the determinations of AH in capsules and rat plasmas and the study on its interactions with three plasma proteins, including bovine serum albumin, cytochrome c and myoglobin were performed successfully. Relative to some previous studies, in this paper the methodologies for the determination of AH in aqueous solution and spiked plasma systems were established, respectively. By comparing the difference between the two work curves of two systems, the matrix effect in plasma samples on the determination of AH by the CE-ECL method was discussed in detail. The results indicated that the effect of the matrix in plasma samples should not be ignored even if no obvious interference was found in the electropherograms and the establishment of method validation in complex samples by the CE-ECL method was necessary.